Zhang Xiaoshun, general manager of Haikang Pharmaceutical Co., Ltd.: focus on API and intermediates to enter the market

[interview with people on chinapharma.com] with the rapid development of the pharmaceutical industry, China's API industry has grown rapidly At present, China has become a large global API supplier In order to help tens of thousands of buyers at home and abroad reach cooperation with domestic API suppliers, the 79th China International Pharmaceutical API / intermediates / packaging / equipment trade (hereinafter referred to as "API China") was held in Xiamen International Convention and Exhibition Center from November 15 to 17 As an Anhui Haikang Pharmaceutical Co., Ltd (hereinafter referred to as "Haikang"), which is committed to the R & D, production, domestic and foreign trade and sales of chemical APIs and intermediates, as well as providing product customization, process improvement, achievement transfer and other services, how can we miss this feast? China Pharmaceutical network interviewed Mr Zhang Xiaoshun, general manager of Haikang, and Mr Zhang shared with us the development of the enterprise in recent years Achievements, and made a detailed plan for the future of the enterprise Mr Zhang Xiaoshun, general manager of Anhui Haikang Pharmaceutical Co., Ltd., interviewed by chinapharma.com, "Haina embraces all rivers, healthy life" Founded in 2009, Haikang is located in Anqing City, Anhui Province, on the lower reaches of the Yangtze River, with superior geographical location and convenient transportation The company mainly produces ganciclovir, valganciclovir hydrochloride, valaciclovir hydrochloride, sirodoxin, repaglinide, sitagliptin, imatinib and related intermediates, and has established stable and good cooperative relations with hundreds of pharmaceutical manufacturers and research institutes at home and abroad President Zhang told the author that after years of development, Haikang's annual output value is over 100 million yuan, and its profits and taxes are over 20 million yuan In addition, in order to put the products into the market, Haikang has been producing in accordance with GMP standards, and has an independent and perfect R & D center In terms of talent reserve, the strength of Haikang can not be underestimated According to Zhang, Haikang has high-quality technical talents and works closely with Zhejiang University of technology, China University of science and technology and Anhui College of traditional Chinese medicine Not only that, Haikang also has an academic advisory group composed of experts and professors, with good medical professional background and experience in drug research and development and market transformation "Our team is a combination of professional elites who are united, brave in development and rigorous in innovation." The staff introduced the product's talent team to the customer in detail, which provided the continuous power for the hot sale of Haikang's products This API China, Haikang has brought us the top-notch products, including ganciclovir, imatinib, silodoxin, etc In addition, Haikang also exhibited some new products, such as this year's development and production of the toluenesulfonate monohydrate, which is mainly used to treat cancer, and esomeprazole sodium, which is used to treat gastric ulcer "We have very high requirements for the purity and quality of our products Next year, we will complete the standardized operation of some products, and hope to get the drug production license and export to the market," Zhang said At present, the API market is booming In addition to domestic buyers, many overseas buyers are looking for excellent products For foreign markets, president Zhang introduced that Haikang has exported some products for overseas markets, mainly in India, Pakistan, Bangladesh, the Middle East, Japan, Russia, Europe and other countries and regions "As you know, at present, the market demand of the industry is increasing, especially in the overseas market As far as Haikang is concerned, the demand for intermediates is relatively large." The rising demand of overseas market and the high quality characteristics of Haikang's products make the enterprise obtain the praise of many customers In response to the appreciation of customers, president Zhang also made a prediction on the future development of the enterprise's products He believed that Haikang's products are not only guaranteed in quality, but also clear in efficacy In addition to the rapid development of the current API and intermediate market, Haikang's products will be more widely used in the future President Zhang told the author that in terms of market, on the basis of stabilizing the domestic market, Haikang will further expand its overseas market and strive to achieve leapfrog development in three to five years "In the future, Haikang will shift from the production of intermediates to the production of APIs, and strive to provide supporting production to foreign and domestic pharmaceutical manufacturers." Zhang said so.